Dybbs Michael 4

What Happened

• Michael Dybbs, an Outside Director of SpyGlass Pharma (SGP), received a grant of 27,400 derivative shares on February 5, 2026. The acquisition price is reported as $0.00, indicating a non‑cash equity award rather than a market purchase or sale.

Key Details

• Transaction date and price: 2026-02-05 @ $0.00 (Transaction code A = Award/Grant; reported as a derivative security).
• Vesting: Subject to continued service as an Outside Director; one‑thirty‑sixth (1/36) of the shares vest each month beginning on the Date of Grant (Feb 5, 2026).
• Shares owned following the transaction: Not specified in the filing.
• Filing timeliness: Form 4 filed Feb 9, 2026 (within the standard reporting window for a Feb 5 transaction).
• Footnote: Vesting occurs on the same calendar day each month (or last day of month if no corresponding day).

Context

• This was an equity compensation award to a director, not a market purchase or sale. Such awards are commonly used to compensate and retain board members and carry vesting conditions tied to continued service. Because no cash was exchanged and the shares are subject to vesting, this filing does not represent an immediate change in tradable shares.